Preventing vertical HIV transmission in the year 2000: Progress and prospects - A review

Placenta

Volumn 22, Issue SUPPL.1, 2001, Pages

  Bulterys, M ^a,b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; DISEASE TRANSMISSION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATHOGENICITY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREGNANCY; PREGNANCY COMPLICATION; REVIEW;

ADULT; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 0035318388     PISSN: 01434004     EISSN: None     Source Type: Journal    
DOI: 10.1053/plac.2001.0671     Document Type: Article

References (77)

1. Adjorlolo G, De Cock KM, Ekpini E, Vetter KM, Sibailly T, Brattegaard K, Yavo D, Doorly R, Whitaker JP, Kestens L, Ou CY, George JR & Gayle HD (1994) Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. J Am Med Assoc, 72, 462-466.
2. Anderson V, Carneiro M, Bulterys M, Douglas G, Polliotti B & Slikker W (2001) Perinatal infections: HIV and co-infections in the placenta and therapeutic interventions (workshop summary). Trophoblast Res, 15, 34-37.
3. Ayers KM, Clive D, Tucker WE, Hajian G & De Miranda P (1996) Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats. Fund Appl Toxicol, 26, 148-158.
4. Baggaley R & Van Praag E (2000) Antiretroviral interventions to reduce mother-to-child transmission of human immunodeficiency virus: challenges for health systems, communities and society. Bull WHO, 78, 1036-1044.
5. Biggar RJ, Miotti PG, Taha TE, Mtimavalye L, Broadhead R, Justesen A, Yellin F, Liomba G, Miley W, Waters D, Chiphangwi JD & Goedert JJ (1996) Perinatal intervention trial in Africa: effect of a birth canal cleansing intervention to prevent HIV transmission. Lancet, 347, 1647-1650.
6. Blanche S, Rouzioux C & Mandelbrot L (1999) Zidovudine-lamivudine for prevention of mother to child HIV-1 transmission: French National Study. Presented at the 6th Conference on Retrovirus and Opportunistic Infections. Chicago, February.
7. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, Ciraru-Vigneron N, Lacroix C, Rouzioux C, Mandelbrot L, Desguerre I, Rotig A, Mayaux MJ & Delfraissy JF (1999) Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet, 354, 1084-1089.
8. Branson B (2000) Rapid tests for HIV antibody. AIDS Reviews, 2, 76-83.
9. Bulterys M & Lepage P (1998) Mother-to-child transmission of HIV. Curr Opin Pediatr, 10, 143-150.
10. Bulterys M, Orloff S, Abrams E, Nesheim S, Palumbo P, Vink P, Lumey LH, Fowler MG & Simonds RJ (1999) Impact of zidovudine post-perinatal exposure prophylaxis on vertical HIV-1 transmission: a prospective cohort study in 4 U.S. cities. Second Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants, Montreal, September, abstract 015.
11. Bulterys M & Fowler MG (2000) Prevention of HIV infection in children. Pediatr Clin North Am, 47, 241-260.
12. Bulterys M, Nesheim S, Abrams E, Palumbo P, Farley J, Lampe M, Fowler MG & the Perinatal Safety Review Working Group (2000a) Lack of evidence of mitochondrial dysfunction in the offspring of HIV-infected women: retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDS Collaborative Transmission Study. Ann NY Acad Sci, 918, 212-221.
13. Bulterys M, Cohen M, Maupin R, Nesheim S, O'Sullivan MJ, Webber M, Lampe M & Fowler MG (2000b) Intrapartum rapid HIV testing and intervention among women without adequate prenatal care: the Mother-Infant Rapid Intervention At Delivery (MIRIAD) study in five US metropolitan areas. 13th Int. AIDS Conf., Durban, July, abstract MoOrC243.
14. Byers RH, Caldwell MB, Davis S, Gwinn M & Lindegren ML (1998) Projection of AIDS and HIV incidence among children born infected with HIV. Stat Med, 17, 169-181.
15. Centers for Disease Control and Prevention (1994) Recommendations of the Public Health Service Task Force on use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR, 43 No. RR-111-21.
16. Centers for Disease Control and Prevention (1995) U.S. Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. MMWR, 44 No. RR-71-14.
17. Centers for Disease Control and Prevention (1998) Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR, 47 No. RR-21-29 (updated on CDC website January 24, 2001).
18. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, Jimenez E, O'Neill E, Bazin B, Delfraissy JF, Culnane M, Coombs R, Elkins M, Moye J, Stratton P & Balsley J (1994) Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med, 331, 1173-1180.
19. Culnane M, Fowler MG, Lee SS, McSherry G, Brady M, O'Donnell K, Mofenson L, Gortmaker SL, Shapiro DE, Scott G, Jimenez E, Moore EC, Diaz C, Flynn PM, Cunningham B & Oleske J for the Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams (1999) Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. J Am Med Assoc, 281, 151-157.
20. Dabis F, Msellati P, Meda N, Welffens-Ekra C, You B, Manigart O, Leroy V, Simonon A, Cartoux M, Combe P, Ouangre A, Ramon R, Ky-Zerbo O, Montcho C, Salamon R, Rouzioux C, Van de Perre P & Mandelbrot L for the DITRAME Study Group (1999) 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double blind placebo-controlled multicentre trial. Lancet, 353, 786-792.
21. Dabis F, Leroy V, Castetbon K, Spira R, Newell ML & Salamon R (2000) Preventing mother-to-child transmission of HIV-1 in Africa in the year 2000. AIDS, 14, 1017-1026.
22. Datta P, Embree JE, Kreiss JK, Ndinya-Achola JO, Braddick M, Temmerman M, Nagelkerke NJ, Maitha G, Holmes KK, Piot P, Pamba HO & Plummer FA (1994) Mother-to-child transmission of human immunodeficiency virus type 1: report from the Nairobi study. J Infect Dis, 170, 1134-1140.
23. DeCock KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff E, Alnwick DJ, Rogers M & Shaffer N (2000) Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. J Am Med Assoc, 283, 1175-1182.
24. Embree JA, Njenga S, Datta P, Nagelkerke NJ, Ndinay-Achola JO, Mohammed Z, Ramhadin S, Bwayo JJ & Plummer FA (2001) Risk factors for postnatal mother-child transmission of HIV-1. AIDS, 14, 2535-2541.
25. Fowler MG, Simonds RJ & Roongpisuthipong A (2000) Update on perinatal HIV transmission. Pediatr Clin North Am, 47, 21-38.
26. Gray G, for the PETRA trial (2000) The PETRA study: early and late efficacy of three short ZDV/3TC combination regimens to prevent mother-to-child transmission of HIV-1. 13th Int. AIDS Conf., Durban, July, abstract LabOrs.
27. Grobman WA & Garcia PM (1999) The cost-effectiveness of voluntary intrapartum rapid human immunodeficiency virus testing for women without adequate prenatal care. Am J Obstet Gynecol, 181, 1062-1071.
28. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Ducar C, Deseyve M, Emel L, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Dransfield K, Bray D, Mmiro F & Jackson JB (1999) Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet, 354, 795-802.
29. Hanson IC, Antonelli TA, Sperling RS, Oleske JM, Cooper E, Culnane M, Fowler MG, Kalish LA, Lee SS, McSherry G, Mofenson L & Shapiro DE (1999) Lack of tumors in infants with perinatal HIV type 1 exposure and fetal/neonatal exposure to zidovudine. J AIDS Hum Retrovirol, 20, 463-467.
30. Institute of Medicine, Committee on Perinatal Transmission of HIV (1999) Reducing the odds: preventing perinatal transmission of HIV in the United States. Washington: National Academy Press.
31. Jacquez JA (1997) Mother-to-child transmission of HIV-1. J AIDS Hum Retrovirol, 16, 284-292.
32. John GC & Kreiss J (1996) Mother-to-child transmission of human immunodeficiency virus type 1. Epidemiol Rev, 18, 149-157.
33. Kourtis AP, Bulterys M, Nesheim SR & Lee FK (2001) Understanding the timing of HIV transmission from mother to infant. J Am Med Assoc 285, 709-712.
34. Kreiss J (1997) Breastfeeding and vertical transmission of HIV-1. Acta Paediatrica, 421(Suppl.), 113-117.
35. Kühn L & Stein ZA (1995) Mother-to-infant HIV transmission: timing, risk factors and prevention. Paediatr Perinat Epidemiol, 9, 1-29.
36. Kumer RM, Uduman SA & Khurranna AK (1995) A prospective study of mother-to-infant transmission in tribal women from India. J AIDS Hum Retrovirol, 9, 238-242.
37. Lallemant M, Lallemant-Le Cœur S, Cheynier D, Nzingoula S, Jourdain G, Sinet M, Dazza MC, Blanche S, Griscelli C & Larouze B (1989) Mother-child transmission of HIV-1 and infant survival in Brazzaville, Congo. AIDS, 3, 643-646.
38. Lallemant M, Jourdain G, Le Cœur S, Kim S, Koetsawang S, Comeau AM, Phoolcharoen W, Essex M, McIntosh K & Vithayasai V for the Perinatal HIV Prevention Trial (Thailand) Investigators (2000) A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. N Engl J Med, 343, 982-991.
39. Landesman SH, Kalish SA, Burns DN, Minkoff H, Fox HE, Zorrilla C, Garcia P, Fowler MG, Mofenson L & Tuomala R for the Women and Infants Transmission Study (1996) Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. N Engl J Med, 334, 1617-1623.
40. Lew J & Fowler MG (1998) Perinatal HIV-1 transmission in the United States and internationally: a review. Trophoblast Research, 12, 85-101.
41. Lindegren ML, Steinberg S & Byers RH (2000) Epidemiology of HIV/ AIDS in children. Pediatr Clin North Am, 47, 1-20.
42. Mandelbrot L, Mayaux MJ, Bongain A, Berrebi A, Moudoub-Jeanpetit Y, Benifla JL, Ciraru-Vigneron N, Le Chenadec J, Blanche S, Delfraissy JF & the French Pediatric HIV Infection Study Group (1996) Obstetric factors and mother-to-child transmission of HIV-1: the French perinatal cohorts. Am J Obstet Cynecol, 175, 661-668.
43. McNicholl JM & Cuenco KT (1999) Host genes and infectious diseases: HIV, other pathogens, and a public health perspective. Am J Prev Med, 16, 141-154.
44. Menu E, M'bopi Keou FX, Lagaye S, Pissard S, Mauclere P, Scarlatti G, Martin J, Goossens M, Chaouat G, Barre-Sinoussi F & the European Network for In Utero Transmission of HIV-1 (1999) Selection of maternal human immunodeficiency virus type 1 variants in human placenta. J Infect Dis, 179, 44-51.
45. Minkoff H & O'Sullivan MJ (1998) The case for rapid HIV testing during labor. J Am Med Assoc, 279, 1743-1744.
46. Mofenson LM (1997) Mother-child HIV-1 transmission: timing and determinants. Obstet Gynecol Clin North Am, 24, 759-784.
47. Mofenson LM, Lambert JS, Stiehm ER, Bethel J, Meyer WA, Whitehouse J, Moye J, Reichelderfer P, Harris DH, Fowler MG, Mathieson BJ & Nemo GJ for the Pediatric AIDS Clinical Trials Group Study 185 Team (1999) Risk factors for perinatal transmission in HIV-infected women and infants receiving zidovudine prophylaxis. N Engl J Med, 341, 385-393.
48. Mofenson LM & McIntyre JA (2000) Advances and research directions in the prevention of mother-to-child HIV-1 transmission. Lancet, 355, 2237-2244.
49. Moodley D, on behalf of the SAINT Investigators Team (2000) The SAINT trial: nevirapine (NVP) versus zidovudine (ZDV) + lamivudine (3TC) in prevention of peripartum HIV transmission. 13th Int. AIDS Conf., Durban, July, abstract LbOr2.
50. Myers G & Korber B (1994) The future of human immunodeficiency virus. In The Evolutionary Biology of Viruses (Ed.) Morse SS, pp. 211-232. New York: Raven Press.
51. Nduati R, John G, Mbori-Ngacha D, Richardson B, Overbaugh J, Mwatha A, Ndinya-Achola J, Bwayo J, Onyango FE, Hughes J & Kreiss J (2000) Effect of breastfeeding and formula feeding on transmission of HIV-1. J Am Med Assoc, 283, 1167-1174.
52. Newell M-L (1998) Mechanisms and timing of mother-to-child transmission of HIV-1. AIDS, 12, 831-837.
53. Newell M-L, Dabis F, Tolley K & Whynes D for the Ghent International Working Group on Mother-to-Child Transmission of HIV (1998) Cost-effectiveness and cost-benefit in the prevention of mother-to-child HIV transmission in sub-Saharan Africa. AIDS, 12, 1571-1580.
54. Newschaffer CJ, Cocroft J, Hauck WW, Fanning T & Turner BJ (1998) Improved birth outcomes associated with enhanced Medicaid prenatal care in drug-using women infected with the human immunodeficiency virus. Obstet Gynecol, 91, 885-891.
55. Olivero OA, Anderson LM, Diwan BA, Haines DC, Harbaugh SW, Moskal TJ, Jones AB, Rice JM, Riggs CW, Logsdon D, Yuspa SH & Poirier MC (1997) Transplacental effects of 3′-azido-2′,3′-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst, 89, 1602-1608.
56. Owor M, Deseyve M, Duefield C, Musisi M, Fleming T, Musoke P, Guay L, Mmiro F & Jackson B (2000) The one year safety and efficacy data of the HIVNET 012 trial. 13th Int. AIDS Conf., Durban, July, abstract LbOr1.
57. Perinatal Safety Review Working Group (2000) Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before five years of age in five United States cohorts. J AIDS, 25, 261-268.
58. Schinazi RF & Nahmias AJ (Eds) (1988) AIDS in Children, Adolescents & Heterosexual Adults: An Interdisciplinary Approach to Prevention, p. 221. New York: Elsevier Press.
59. Schwartz DA, Sungkarat S, Shaffer N, Laosakkitiboran J, Supapol W, Charoenpanich P, Chuangsuwanich T & Mastro TD (2000) Placental abnormalities associated with HIV-1 infection and perinatal transmission, Bangkok, Thailand. J Infect Dis, 182, 1652-1657.
60. Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, Chotpitayasunondh T, Chearskul S, Roongpisuthipong A, Chinayon P, Karon J, Mastro TD & Simonds RJ on behalf of the Bangkok Collaborative Perinatal HIV Transmission Study Group (1999) Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet, 353, 773-780.
61. Simonds RJ, Steketee R, Nesheim S, Matheson P, Palumbo P, Alger L, Abrams EJ, Orloff S, Lindsay M, Bardeguez AD, Vink P, Byers R, Rogers M & the Perinatal AIDS Collaborative Transmission Studies (PACTS) (1998) Impact of zidovudine use on risk and risk factors for perinatal HIV transmission. AIDS, 12, 301-308.
62. Sperling RS, Shapiro DE, Coombs RW, Todd JA, Herman SA, McSherry GD, O'Sullivan MJ, Van Dyke RB, Jimenez E, Rouzioux C, Flynn PM & Sullivan JL for the Pediatric AIDS Clinical Trials Protocol 076 Study Group (1996) Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med, 335, 1621-1629.
63. Sperling RS, Shapiro DE, McSherry GD, Britto P, Cunningham BE, Culnane M, Coombs RW, Scott G, Van Dyke RB, Shearer WT, Jimenez E, Diaz C, Harrison DD & Delfraissy JF (1998) Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study. AIDS, 12, 1805-1813.
64. St. Louis ME, Kamenga M, Brown C, Nelson AM, Manzila T, Batter V, Behets F, Kabagabo U, Ryder RW, Oxtoby M, Quinn TC & Heyward WL (1993) Risk for perinatal HIV-1 transmission according to maternal immunologic, virologic, and placental factors. J Am Med Assoc, 269, 2853-2859.
65. Stringer JS & Rouse DJ (1999) Rapid testing and zidovudine treatment to prevent vertical transmission of HIV in unregistered parturients: a costeffectiveness analysis. Obstet Gynecol, 94, 34-40.
66. Temmerman M, Chomba EN, Ndinya-Achola J, Plummer FA, Coppens M & Piot P (1994) Maternal human immunodeficiency virus-1 infection and pregnancy outcome. Obstet Gynecol, 83, 495-501.
67. Temmerman M, Nyong'o AO, Bwayo J, Fransen K, Coppens M & Piot P (1995) Risk factors for mother-to-child transmission of human immunodeficiency virus-1 infection. Am J Obstet Gynecol, 172, 700-705.
68. Van de Perre P, Simonon A, Msellati P, Hitimana DG, Vaira D, Bazubagira A, Van Goethem C, Stevens AM, Karita E, Sondag-Thull D, Dabis F & Lepage P (1991) Postnatal transmission of human immunodeficiency virus type 1 from mother to infant: a prospective cohort study in Kigali, Rwanda. N Engl J Med, 325, 593-598.
69. Van Dyke RB, Korber BT, Popek E, Macken C, Widmayer SM, Bardeguez A, Celine Hanson I, Wiznia A, Luzuriaga K, Viscarello RR, Wolinsky S & the Ariel Core Investigators (1999) The Ariel Project: a prospective cohort study of maternal-child transmission of HIV-1 in the era of maternal antiretroviral therapy. J Infect Dis, 179, 319-328.
70. Van Rompay KK, Marthas ML, Lifson JD, Berardi CJ, Vasquez GM, Agatep E, Dehqanzada ZA, Cundy KC, Bischofberger N & Pedersen NC (1998) Administration of PMPA for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. AIDS Res Hum Retrovir, 14, 761-773.
71. Van Rompay KK, Miller MD, Marthas ML, Margot NA, Dailey PJ, Canfield DR, Tarara RP, Cherrington JM, Aguirre NL, Bischofberger N & Pedersen NC (2000) Prophylactic and therapeutic benefits of short-term PMPA administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. J Virol, 74, 1767-1774.
72. Wade NA, Birkhead GS, Warren BL, Charbonneau TT, French PT, Wang L, Baum JB, Tesoriero JM & Savicki R (1998) Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med, 339, 1409-1414.
73. Wade NA, Birkhead GS & French PT (1999) Short courses of zidovudine and perinatal transmission of HIV [letter]. N Engl J Med, 340, 1042-1043.
74. Wiktor SZ, Ekpini E, KaronJM, Nkengasong J, Maurice C, Severin ST, Roels TH, Kouassi MK, Lackritz EM & Coulibaly IM (1999) Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial. Lancet, 353, 781-785.
75. Wiktor SZ, Leroy V, Ekpini ER, Alioum A, Karon J, Msellati P, Hudgens M, Meda M & Greenberg AE (2000) 24-month efficacy of short-course maternal zidovudine for the prevention of mother-to-child transmission in a breastfeeding population: a pooled analysis of two randomized clinical trials in West Africa. 13th Int. AIDS Conf., Durban, July 2000, abstract TuOrB354.
76. Working Group on Mother-to-Child Transmission of HIV (1995) Rates of mother-to-child transmission of HIV-1 in Africa, America and Europe: results from 13 perinatal studies. J AIDS Hum Retrovirol, 8, 506-510.
77. World Health Organization and United Nations Programme on AIDS (1999) HIV in Pregnancy: A Review. Geneva, Switzerland: WHO (publication number WHO/CHS/RHR/99.15).